Faron Reports 12-Month Survival Results of Bexmarilimab in P-I/II (MATINS) Study for the Treatment of Solid Tumor
Shots:
- The P-I/II (MATINS) study evaluates bexmarilimab as monothx. in 90 patients with 10 solid tumor cohorts who received 3 courses of treatment & had scheduled tumor imaging at cycle 4 & completed 12mos. survival follow-up
- The results showed that 65% of patients were alive who benefited from treatment with bexmarilimab @12mos. over 11% who did not benefit, the strongest survival benefit was observed, 12mos. survival (100% in benefited patients vs 0% who did not benefit), was well tolerated with no new safety signals & no TRAEs that resulted in a decrease or modification of dosing
- Bexmarilimab is wholly-owned precision immunotherapy that provides long-term immune stimulation for cancers by targeting myeloid cell function
Ref: Cision | Image: Faron
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
